PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
作者： Ruoyu Ni , Anna Marie Mulligan , Cherry Have , Frances P. O??Malley
DOI: 10.1097/01.PAI.0000213138.01536.2E
关键词:
摘要: Given the important prognostic and predictive utility of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ErbB2) [human epidermal growth factor receptor-2 (HER2/neu)] in breast cancer, it is recommended that ErbB2 testing be performed on all invasive cancers at time diagnosis
lww.com 
sci-hub.se 参考文章(32)
Marta Salido, Ignasi Tusquets, Josep M Corominas, Marta Suarez, Blanca Espinet, Cristina Corzo, Meritxell Bellet, Xavier Fabregat, Sergi Serrano, Francesc Solé, Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry Breast Cancer Research. ,vol. 7, pp. 1- 7 ,(2005) , 10.1186/BCR996
S Paik, R Hazan, E R Fisher, R E Sass, B Fisher, C Redmond, J Schlessinger, M E Lippman, C R King, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology. ,vol. 8, pp. 103- 112 ,(1990) , 10.1200/JCO.1990.8.1.103
Luis Alberto Rubio-Martinez, José Maria Vera-Roman, Comparative assays for the HER-2/neu oncogene status in breast cancer. Archives of Pathology & Laboratory Medicine. ,vol. 128, pp. 627- 633 ,(2004) , 10.1043/1543-2165(2004)128<627:CAFTNO>2.0.CO;2
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
K Leitzel, Y Teramoto, K Konrad, V M Chinchilli, G Volas, H Grossberg, H Harvey, L Demers, A Lipton, Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 1129- 1135 ,(1995) , 10.1200/JCO.1995.13.5.1129
S Toikkanen, H Helin, J Isola, H Joensuu, Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. Journal of Clinical Oncology. ,vol. 10, pp. 1044- 1048 ,(1992) , 10.1200/JCO.1992.10.7.1044
C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, G Pettinato, L Panico, A D'Antonio, A R Bianco, S De Placido, c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology. ,vol. 14, pp. 2702- 2708 ,(1996) , 10.1200/JCO.1996.14.10.2702
José Baselga, Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials Oncology. ,vol. 61, pp. 14- 21 ,(2001) , 10.1159/000055397
C Wright, S Nicholson, B Angus, JRC Sainsbury, J Farndon, J Cairns, AL Harris, CHW Horne, Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer. ,vol. 65, pp. 118- 121 ,(1992) , 10.1038/BJC.1992.22
Priti Lal, Paulo A. Salazar, Marc Ladanyi, Beiyun Chen, Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification The Journal of Molecular Diagnostics. ,vol. 5, pp. 155- 159 ,(2003) , 10.1016/S1525-1578(10)60467-9